Skip to main content
Erschienen in: Virchows Archiv 5/2016

01.03.2016 | Original Article

HOXB13 protein expression in metastatic lesions is a promising marker for prostate origin

verfasst von: Justine Varinot, Adéline Furudoï, Sarah Drouin, Véronique Phe, Raphaele Renard Penna, Morgan Roupret, Marc-Olivier Bitker, Olivier Cussenot, Eva Compérat

Erschienen in: Virchows Archiv | Ausgabe 5/2016

Einloggen, um Zugang zu erhalten

Abstract

The HOXB13 gene is a member of the homeobox gene family, and prostate development depends on HOXB13 function. HOXB13 is a very sensitive and specific marker of prostate tissue and prostate cancer. When the origin of a tumor in a resection specimen or in biopsy material is unclear, it allows determining the prostate as the primary. Our aim was to determine whether HOXB13 has similar sensitivity for determining prostate origin of lymph node and bone metastases. We retrieved cases of lymph node and bone metastases of histologically confirmed prostate cancer (PCa) and selected lymph node metastases of urothelial carcinoma (UCa). A panel of antibodies against HOXB13, PSA, ERG, Androgen receptors, p504S, p63, GATA-3, CK7, and Uroplakin 2 and 3 was tested on these tissue samples. Two pathologists analysed and scored staining as either 0 (negative) or + (positive). The selected cohort consisted of 74 cases of lymph node and 15 of bone metastases of PCa and 15 of lymph node metastases of UCa. HOXB13 was expressed in 93 % of lymph node and in 33 % of bone metastases of PCa. All lymph node metastases of UCa were negative. Sensitivity of HOXB13 as a marker for prostate origin in lymph node metastases was 93 % and for bone metastases 33 %. Inter-observer variability in assessment of staining was good, as only two (1.9 %) of lymph node metastasis of PCa were discordant. HOXB13 is a useful marker for prostate origin when doubt exists regarding the site of the primary of a metastatic lesion. On bone metastases, HOXB13 immunohistochemistry performed less well, probably due to the use of tissue decalcification.
Literatur
1.
Zurück zum Zitat Ewing CM, Ray AM, Lange EM, Zuhlke KA, Robbins CM, Tembe WD, et al. (2012) Germline mutations in HOXB13 and prostate-cancer risk. N Engl J Med 366:141–149CrossRefPubMedPubMedCentral Ewing CM, Ray AM, Lange EM, Zuhlke KA, Robbins CM, Tembe WD, et al. (2012) Germline mutations in HOXB13 and prostate-cancer risk. N Engl J Med 366:141–149CrossRefPubMedPubMedCentral
2.
Zurück zum Zitat Varinot J, Cussenot O, Roupret M, Conort P, Bitker M-O, Chartier-Kastler E, et al. (2013) HOXB13 is a sensitive and specific marker of prostate cells, useful in distinguishing between carcinomas of prostatic and urothelial origin. Virchows Arch 463:803–809CrossRefPubMed Varinot J, Cussenot O, Roupret M, Conort P, Bitker M-O, Chartier-Kastler E, et al. (2013) HOXB13 is a sensitive and specific marker of prostate cells, useful in distinguishing between carcinomas of prostatic and urothelial origin. Virchows Arch 463:803–809CrossRefPubMed
3.
Zurück zum Zitat MB A, Trpkov K, Lopez-Beltran A, Grignon D, Members of the ISUP Immunohistochemistry in Diagnostic Urologic Pathology Group (2014) Best practices recommendations in the application of immunohistochemistry in the bladder lesions: report from the International Society of Urologic Pathology consensus conference. Am J Surg Pathol 38:e20–e34 MB A, Trpkov K, Lopez-Beltran A, Grignon D, Members of the ISUP Immunohistochemistry in Diagnostic Urologic Pathology Group (2014) Best practices recommendations in the application of immunohistochemistry in the bladder lesions: report from the International Society of Urologic Pathology consensus conference. Am J Surg Pathol 38:e20–e34
4.
Zurück zum Zitat Smith SC, Palanisamy N, Zuhlke KA, Johnson AM, Siddiqui J, Chinnaiyan AM, HOXB13, et al. (2014) G84E-related familial prostate cancers: a clinical, histologic, and molecular survey. Am J Surg Pathol 38:615–626CrossRefPubMedPubMedCentral Smith SC, Palanisamy N, Zuhlke KA, Johnson AM, Siddiqui J, Chinnaiyan AM, HOXB13, et al. (2014) G84E-related familial prostate cancers: a clinical, histologic, and molecular survey. Am J Surg Pathol 38:615–626CrossRefPubMedPubMedCentral
5.
Zurück zum Zitat Jourdan F, Sebbagh N, Comperat E, Mourra N, Flahault A, Olschwang S, et al. (2003) Tissue microarray technology: validation in colorectal carcinoma and analysis of p53, hMLH1, and hMSH2 immunohistochemical expression. Virchows Arch 443:115–121CrossRefPubMed Jourdan F, Sebbagh N, Comperat E, Mourra N, Flahault A, Olschwang S, et al. (2003) Tissue microarray technology: validation in colorectal carcinoma and analysis of p53, hMLH1, and hMSH2 immunohistochemical expression. Virchows Arch 443:115–121CrossRefPubMed
6.
Zurück zum Zitat Parwani AV, Herawi M, Epstein JI (2006) Pleomorphic giant cell adenocarcinoma of the prostate: report of 6 cases. Am J Surg Pathol 30:1254–1259CrossRefPubMed Parwani AV, Herawi M, Epstein JI (2006) Pleomorphic giant cell adenocarcinoma of the prostate: report of 6 cases. Am J Surg Pathol 30:1254–1259CrossRefPubMed
7.
Zurück zum Zitat Gurel B, Ali TZ, Montgomery EA, Begum S, Hicks J, Goggins M, et al. (2010) NKX3.1 as a marker of prostatic origin in metastatic tumors. Am J Surg Pathol 34:1097–1105CrossRefPubMedPubMedCentral Gurel B, Ali TZ, Montgomery EA, Begum S, Hicks J, Goggins M, et al. (2010) NKX3.1 as a marker of prostatic origin in metastatic tumors. Am J Surg Pathol 34:1097–1105CrossRefPubMedPubMedCentral
8.
Zurück zum Zitat Ud Din N, Qureshi A, Mansoor S (2011) Utility of p63 immunohistochemical stain in differentiating urothelial carcinomas from adenocarcinomas of prostate. Indian J Pathol Microbiol 54:59–62CrossRefPubMed Ud Din N, Qureshi A, Mansoor S (2011) Utility of p63 immunohistochemical stain in differentiating urothelial carcinomas from adenocarcinomas of prostate. Indian J Pathol Microbiol 54:59–62CrossRefPubMed
9.
Zurück zum Zitat Jiang Z, Woda BA, Rock KL, Xu Y, Savas L, Khan A, et al. (2001) P504S: a new molecular marker for the detection of prostate carcinoma. Am J Surg Pathol 25:1397–1404CrossRefPubMed Jiang Z, Woda BA, Rock KL, Xu Y, Savas L, Khan A, et al. (2001) P504S: a new molecular marker for the detection of prostate carcinoma. Am J Surg Pathol 25:1397–1404CrossRefPubMed
10.
Zurück zum Zitat Luo J, Zha S, Gage WR, Dunn TA, Hicks JL, Bennett CJ, et al. (2002) Alpha-methylacyl-CoA racemase: a new molecular marker for prostate cancer. Cancer Res 62:2220–2226PubMed Luo J, Zha S, Gage WR, Dunn TA, Hicks JL, Bennett CJ, et al. (2002) Alpha-methylacyl-CoA racemase: a new molecular marker for prostate cancer. Cancer Res 62:2220–2226PubMed
11.
Zurück zum Zitat Chuang A-Y, DeMarzo AM, Veltri RW, Sharma RB, Bieberich CJ, Epstein JI (2007) Immunohistochemical differentiation of high-grade prostate carcinoma from urothelial carcinoma. Am J Surg Pathol 31:1246–1255CrossRefPubMed Chuang A-Y, DeMarzo AM, Veltri RW, Sharma RB, Bieberich CJ, Epstein JI (2007) Immunohistochemical differentiation of high-grade prostate carcinoma from urothelial carcinoma. Am J Surg Pathol 31:1246–1255CrossRefPubMed
12.
Zurück zum Zitat JI E, Egevad L, PA H, Montironi R, Members of the ISUP Immunohistochemistry in Diagnostic Urologic Pathology Group (2014) Best practices recommendations in the application of immunohistochemistry in the prostate: report from the International Society of Urologic Pathology consensus conference. Am J Surg Pathol 38:e6–19 JI E, Egevad L, PA H, Montironi R, Members of the ISUP Immunohistochemistry in Diagnostic Urologic Pathology Group (2014) Best practices recommendations in the application of immunohistochemistry in the prostate: report from the International Society of Urologic Pathology consensus conference. Am J Surg Pathol 38:e6–19
Metadaten
Titel
HOXB13 protein expression in metastatic lesions is a promising marker for prostate origin
verfasst von
Justine Varinot
Adéline Furudoï
Sarah Drouin
Véronique Phe
Raphaele Renard Penna
Morgan Roupret
Marc-Olivier Bitker
Olivier Cussenot
Eva Compérat
Publikationsdatum
01.03.2016
Verlag
Springer Berlin Heidelberg
Erschienen in
Virchows Archiv / Ausgabe 5/2016
Print ISSN: 0945-6317
Elektronische ISSN: 1432-2307
DOI
https://doi.org/10.1007/s00428-016-1917-x

Weitere Artikel der Ausgabe 5/2016

Virchows Archiv 5/2016 Zur Ausgabe

Editorial

In this issue

Neu im Fachgebiet Pathologie